Search results for "DISCOVERY"

showing 10 items of 4119 documents

Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

2016

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kinetics studies showed very different stabilities over 24 h; however, fast reductive activation via E. coli nitroreductase could be confirmed for both panels. The anticancer activity and signaling inhibition of the compounds against various human cancer cell lines were evaluated in cell culture. These data, together with molecular docking simulations, revealed distinct differences in the impact of …

medicine.drug_classPharmacology010402 general chemistry01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitor03 medical and health sciencesNitroreductase0302 clinical medicinetyrosine kinase inhibitorsDrug DiscoverymedicinecancerEpidermal growth factor receptorGeneral Pharmacology Toxicology and PharmaceuticsPharmacologybiologyhypoxiaSunitinibChemistryOrganic ChemistryProdrugtargeted therapeutic0104 chemical sciencesSettore CHIM/03 - Chimica Generale E InorganicaCell culture030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibprodrugTyrosine kinasemedicine.drugChemMedChem
researchProduct

(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.

2015

Breast cancer remains the leading cause of cancer-related death among women. The invasive triple-negative subtype is unresponsive to estrogen therapy, and few effective treatments are available. In search of new chemical scaffolds to target this disease, we conducted a phenotypic screen against the human breast carcinoma cell lines MDA-MB-231, MA11, and MCF-7 using terrestrial natural products. Natural products that preferentially inhibited proliferation of triple-negative MDA-MB-231 cells over estrogen receptor-positive cells were further studied; herein we focused on the abietanes. The activity of the abietane carnosol prompted us to generate a focus library from the readily available (+)…

medicine.drug_classPhenotypic screeningApoptosisTriple Negative Breast NeoplasmsPharmacologyCarnosolchemistry.chemical_compoundStructure-Activity RelationshipBreast cancerCell Line TumorDrug DiscoverymedicineHumansTriple-negative breast cancerCell ProliferationPharmacologyBiological ProductsDose-Response Relationship DrugMolecular StructureCell growthDrug discoveryOrganic ChemistryStereoisomerismGeneral MedicineTriple Negative Breast Neoplasmsmedicine.diseaseAntineoplastic Agents PhytogenicchemistryEstrogenAbietanesMCF-7 CellsFemaleDrug Screening Assays AntitumorEuropean journal of medicinal chemistry
researchProduct

Kaempferol as a dietary anti-inflammatory agent: current therapeutic standing

2020

Inflammation is a physiological response to different pathological, cellular or vascular damages due to physical, chemical or mechanical trauma. It is characterized by pain, redness, heat and swelling. Current natural drugs are carefully chosen as a novel therapeutic strategy for the management of inflammatory diseases. Different phytochemical constituents are present in natural products. These phytochemicals have high efficacy both in vivo and in vitro. Among them, flavonoids occur in many foods, vegetables and herbal medicines and are considered as the most active constituent, having the ability to attenuate inflammation. Kaempferol is a polyphenol that is richly found in fruits, vegetabl…

medicine.drug_classPhytochemicalsAnti-Inflammatory AgentsPharmaceutical ScienceBiological AvailabilityReviewChemical FractionationAnti-inflammatoryAnalytical Chemistrylcsh:QD241-441therapeutic utility03 medical and health scienceschemistry.chemical_compoundStructure-Activity Relationship0302 clinical medicinelcsh:Organic chemistryDrug DiscoveryToxicity TestsmedicineAnimalsHumansPhysical and Theoretical ChemistryKaempferols030304 developmental biologyTherapeutic strategyFlavonoids0303 health sciencesBiological ProductskaempferolPlants MedicinalTraditional medicineOrganic Chemistryfood and beveragesKaempferol Anti-Inflammatory TherapyBioavailabilityReview articlechemistryPhytochemicalChemistry (miscellaneous)Polyphenolinflammation030220 oncology & carcinogenesisDietary SupplementsMolecular MedicineKaempferol
researchProduct

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

2011

Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies w…

medicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryMonoclonal antibodyAntibody fragmentsNeoplasm ProteinNeoplasmsDrug DiscoveryImmunoglobulin FragmentmedicineAnimalsHumansImmunoglobulin FragmentsAnti-EGFRPharmacologyChemotherapyMonoclonal antibodiebiologybusiness.industryAnimalDrug Discovery3003 Pharmaceutical ScienceAnti-VEGFCancerAntibodies MonoclonalImmunotherapymedicine.diseaseAntibody fragmentNeoplasm ProteinsAnti-HER2Clinical PracticeTreatment OutcomeExpert opinionImmunologybiology.proteinNeoplasmMonoclonal antibodiesImmunotherapyAnti-EGFR; Anti-HER2; Anti-VEGF; Antibody fragments; Monoclonal antibodiesAntibodybusinessHuman
researchProduct

Design, synthesis, DNA-binding and cytotoxicity evaluation of new potential combilexines

2002

Combilexines, compounds in which a DNA intercalator is linked to a minor groove binding component, interact with the DNA in a sequence specific manner to yield in most cases compounds with anticancer activity. A series of new compounds closely related to netropsin in which the two components were linked by an amide group was synthesised as potential combilexines. As some of these compounds showed cytotoxic activity in vitro, an attempt was made to rationalise their mechanism of action. The DNA binding characteristics of the carboxamides were evaluated by thermal denaturation experiments and by ethidium bromide displacement assay. Their ability to inhibit the topoisomerase I was also determi…

medicine.drug_classStereochemistryAntineoplastic AgentsCarboxamideNucleic Acid DenaturationChemical synthesischemistry.chemical_compoundDrug DiscoveryTumor Cells CulturedmedicineA-DNAPharmacologyBinding SitesbiologyTopoisomeraseOrganic ChemistryDNAGeneral MedicineIntercalating AgentschemistryMechanism of actionBiochemistryNetropsinDrug Designbiology.proteinDrug Screening Assays AntitumorTopoisomerase I Inhibitorsmedicine.symptomEthidium bromideCell DivisionDNAEuropean Journal of Medicinal Chemistry
researchProduct

Synthesis, biological evaluation, and structure-activity relationship study of novel cytotoxic aza-caffeic acid derivatives.

2010

Abstract Three series of aza-caffeic acid derivatives with different linkers were designed and synthesized. Each of the synthesized derivatives was then used in cytotoxicity screening on either 8 or 12 human cancer cell lines. The structure–activity relationships on three structural regions A, B, and C are analyzed in detail, indicating that a nine bond linker B, containing a piperazine unit, is the most favorable linker leading to the generation of molecules with potent cytotoxicities. Compound ( E )-1-(4-(3,4-dichlorobenzyl)piperazin-1-yl)-3-(4-(4-ethoxybenzyloxy)-3,5-dimethoxyphenyl)prop-2-en-1-one ( 80 ) exhibited the most significant and selective cytotoxicity to KB, BEL7404, K562, and…

medicine.drug_classStereochemistryClinical BiochemistryPharmaceutical ScienceCarboxamideBiochemistryChemical synthesischemistry.chemical_compoundStructure-Activity RelationshipCaffeic AcidsCell Line TumorDrug DiscoverymedicineCaffeic acidStructure–activity relationshipHumansCytotoxicityCaffeic acid phenethyl esterMolecular BiologyAza CompoundsChemistryOrganic ChemistryFlow CytometryPiperazineBiochemistryMolecular MedicineLinkerBioorganicmedicinal chemistry
researchProduct

Synthesis of fluorine-18 labeled sulfonureas as ?-cell imaging agents

2001

Tolbutamide (1) and glyburide (7) are hypoglycemic drugs used to stimulate insulin secretion in type 2 diabetic patients. We have synthesized their fluorine-18 labeled analogs, 1-[(4-[ 18 F]fluorobenzenesulfonyl)]-3-butyl]urea (p-[ 18 F]fluorotolbutamide, 3a) and N-{4-[β-(2-[ 18 F]fluoroethoxybenzene carboxamido)ethyl]benzenesulfonyl)-N'-cyclohexylurea (2-[ 18 F]fluoroethoxyglyburide, 6a) as β-cell imaging agents. Compound 3a was synthesized via two approaches: One-step synthesis via nucleophilic substitution of p-nitrotolbutamide (2) with K[ 18 F]/Kryptofix 2.2.2 in either CH 3 CN or DMSO gave a complicated mixture; a two-step synthesis via preparation and reaction of 4-[ 18 F]fluorobenzen…

medicine.drug_classStereochemistryOrganic ChemistryCarboxamideAlkylationBiochemistryChemical synthesisMedicinal chemistryHigh-performance liquid chromatographyAnalytical Chemistrychemistry.chemical_compoundTolbutamidechemistryYield (chemistry)Drug DiscoverymedicineUreaNucleophilic substitutionRadiology Nuclear Medicine and imagingSpectroscopymedicine.drugJournal of Labelled Compounds and Radiopharmaceuticals
researchProduct

Botanicals and phytochemicals from the bark of Hypericum roeperianum (Hypericaceae) had strong antibacterial activity and showed synergistic effects …

2021

Abstract Ethnopharmacological relevance Infections due to multidrug-resistant (MDR) bacteria constitute a real problem in the public health worldwide. Hypericum roeperianum Schimp. ex A. Rich (Hypericaceae) is used traditionally for treatment of various ailments such as abdominal pains, constipation, diarrhea, indigestion, nausea, and bacterial diseases. Aim of the study This study was aimed at investigating the antibacterial and antibiotic-modifying activity of the crude methanol extracts (HRB), ethyl-acetate soluble fraction (HRBa), residual material (HRBb), and 11 compounds from the bark of Hypericum roeperianum against multi-drug resistant (MDR) bacteria expressing active efflux pumps. …

medicine.drug_classTetracyclinePhytochemicalsAntibioticsMicrobial Sensitivity Tests03 medical and health sciences0302 clinical medicineDrug Resistance Multiple BacterialDrug Discoverymedicine030304 developmental biologyPharmacologyDoxycycline0303 health sciencesBacteriaTraditional medicinebiologyPlant ExtractsChemistryMembrane Transport ProteinsDrug Synergismbiology.organism_classificationAnti-Bacterial AgentsMultiple drug resistancePhytochemical030220 oncology & carcinogenesisPlant BarkEffluxAntibacterial activityHypericumBacteriamedicine.drugJournal of Ethnopharmacology
researchProduct

Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib

2019

Despite the huge success of tyrosine kinase inhibitors as anticancer agents, severe side effects are a major problem. In order to overcome this drawback, the first hypoxia-activatable 2-nitroimidazole-based prodrugs of the clinically approved ALK and c-MET inhibitor crizotinib were developed. The 2-aminopyridine functionality of crizotinib (essential for target kinase binding) was considered as ideal position for prodrug derivatization. Consequently, two different prodrugs were synthesized with the nitroimidazole unit attached to crizotinib either via carbamoylation (A) or alkylation (B) of the 2-aminopyridine moiety. The successful prodrug design could be proven by docking studies and a dr…

medicine.drug_classTyrosine kinase inhibitorAntineoplastic Agents01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitorStructure-Activity Relationshipchemistry.chemical_compoundDrug DevelopmentCrizotinibIn vivoDrug DiscoverymedicineHumansAnaplastic Lymphoma KinaseProdrugsHypoxiaProdrugProtein Kinase InhibitorsMolecular BiologyCells CulturedCell ProliferationNitroimidazoleDose-Response Relationship DrugMolecular StructureCrizotinib010405 organic chemistryChemistryNitroimidazoleOrganic ChemistryProto-Oncogene Proteins c-metProdrugCell Hypoxia0104 chemical sciences010404 medicinal & biomolecular chemistrySettore CHIM/03 - Chimica Generale E InorganicaDocking (molecular)Cancer researchDrug Screening Assays AntitumorKinase bindingTyrosine kinasemedicine.drugBioorganic Chemistry
researchProduct

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct